← All trials
NCT01756430
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2012
- Primary completion
- Sep 1, 2013
- Completion date
- Sep 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 238
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Chong Kun Dang PharmaceuticalLead sponsor
- Chonnam National UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Sejong General HospitalOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Hanyang UniversityOverall official - principal investigator
- Keimyung UniversityOverall official - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- Ilsan HospitalOverall official - principal investigator
- Soonchunhyang UniversityOverall official - principal investigator
- Wonju Christian HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.